

## AI-Based design of functional therapeutic antibodies

Yanay Ofran

### ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name: Biolojic Design \* Website: www.biolojic.com \*

CEO name: Yanay Ofran

Select a CATEGORY: Biotech/Pharma

- **Is AI revolutionizing drug discovery and clinical development?**
- Advancements in the space of bio-convergence

You may delete the section instructions, leaving only the bolded bullet title  
Answers below should not exceed 60 words per question:

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. –

Biolojic Design leverages AI and computational design to transform human antibodies into intelligent, programmable medicines. Our platform has produced the world's first AI-designed antibody to enter clinical trials, now in phase II, showcasing the transformative potential of our approach to generate better and safer drugs. Biolojic's technology enables human antibodies to be re-engineered into programmable switches with diverse and tailored functionalities, including agonism, antagonism, and conditional binding. This unique capability allows us to create multi-specific antibodies that operate as logic gates, executing "and" or "xor" functions to achieve precision targeting. Biolojic's pipeline focuses on autoimmune diseases and immuno-oncology, address validated pathways with novel compounds to unlock large unmet needs. In addition to the fully owned pipeline, Biolojic also partners with pharma companies to develop antibodies designed by our platform, with current deals totaling over a \$1B in upfront and milestone payments.

